Advanced

Low dose Zebularine treatment enhances immunogenicity of tumor cells

Liu, Hua LU ; Xue, Zhongtian LU ; Sjögren, Hans Olof LU ; Salford, Leif LU and Widegren, Bengt LU (2007) In Cancer Letters 257(1). p.107-115
Abstract
Strategy: We have investigated how alterations in gene expression induced by the demethylating drug Zebularine affect the immune response tumor cells elicit. The rational has been to treat syngeneic rat colon cancer cells with Zebularine at different concentrations and then use these cells to study gene expression of different genes involved in cancer immunogenicity. Gene expressions were monitored by semi-quantitative PCR and real-time PCR. Results: Intriguingly there was a large increase in the production of indoleamine 2,3-dioxygenase (IDO) after treatment with 100 mu M Zebularine as compared with untreated tumor cells, whereas treatment with 20 mu M Zebularine caused a significant decrease of the IDO production. After immunization with... (More)
Strategy: We have investigated how alterations in gene expression induced by the demethylating drug Zebularine affect the immune response tumor cells elicit. The rational has been to treat syngeneic rat colon cancer cells with Zebularine at different concentrations and then use these cells to study gene expression of different genes involved in cancer immunogenicity. Gene expressions were monitored by semi-quantitative PCR and real-time PCR. Results: Intriguingly there was a large increase in the production of indoleamine 2,3-dioxygenase (IDO) after treatment with 100 mu M Zebularine as compared with untreated tumor cells, whereas treatment with 20 mu M Zebularine caused a significant decrease of the IDO production. After immunization with syngeneic tumor cells, spleen cells were isolated and restimulated in vitro with irradiated tumor cells. Immune reactivity was measured by proliferation, and production of interferon gamma and interleukinl0. The immunogenicity of tumor cells treated in vitro with a low dose of Zebularine increased, whereas it decreased after high dose exposure. The inhibition of immunogenicity by 100 mu M Zebularine was shown to be counteracted by the IDO inhibitor I methyl-tryptophan (1MT), confirming that this effect of Zebularine is mainly caused by IDO induction. Differences using Zebularine-treated or non-treated cells for in vitro restimulation were marginal. Conclusion: Low dose treatment with Zebularine (20 mu M) decreases the production of the immunosuppressive IDO from rat colon cancer cells and enhances their immunogenicity, whereas high dose Zebularine treatment (100 mu M) enhances the IDO production from the cancer cells and suppresses their immunogenicity. This immunosuppression should be considered when cancer is treated with Zebularine or drugs acting in a similar way. (C) 2007 Published by Elsevier Ireland Ltd. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
DNA methylation, zebularine, IDO, immunogenicity
in
Cancer Letters
volume
257
issue
1
pages
107 - 115
publisher
Elsevier
external identifiers
  • wos:000250597300011
  • scopus:34648820287
ISSN
1872-7980
DOI
10.1016/j.canlet.2007.07.013
language
English
LU publication?
yes
id
b4520921-555e-4137-9a59-4c309d082574 (old id 654156)
date added to LUP
2007-12-13 08:43:24
date last changed
2017-04-16 04:15:34
@article{b4520921-555e-4137-9a59-4c309d082574,
  abstract     = {Strategy: We have investigated how alterations in gene expression induced by the demethylating drug Zebularine affect the immune response tumor cells elicit. The rational has been to treat syngeneic rat colon cancer cells with Zebularine at different concentrations and then use these cells to study gene expression of different genes involved in cancer immunogenicity. Gene expressions were monitored by semi-quantitative PCR and real-time PCR. Results: Intriguingly there was a large increase in the production of indoleamine 2,3-dioxygenase (IDO) after treatment with 100 mu M Zebularine as compared with untreated tumor cells, whereas treatment with 20 mu M Zebularine caused a significant decrease of the IDO production. After immunization with syngeneic tumor cells, spleen cells were isolated and restimulated in vitro with irradiated tumor cells. Immune reactivity was measured by proliferation, and production of interferon gamma and interleukinl0. The immunogenicity of tumor cells treated in vitro with a low dose of Zebularine increased, whereas it decreased after high dose exposure. The inhibition of immunogenicity by 100 mu M Zebularine was shown to be counteracted by the IDO inhibitor I methyl-tryptophan (1MT), confirming that this effect of Zebularine is mainly caused by IDO induction. Differences using Zebularine-treated or non-treated cells for in vitro restimulation were marginal. Conclusion: Low dose treatment with Zebularine (20 mu M) decreases the production of the immunosuppressive IDO from rat colon cancer cells and enhances their immunogenicity, whereas high dose Zebularine treatment (100 mu M) enhances the IDO production from the cancer cells and suppresses their immunogenicity. This immunosuppression should be considered when cancer is treated with Zebularine or drugs acting in a similar way. (C) 2007 Published by Elsevier Ireland Ltd.},
  author       = {Liu, Hua and Xue, Zhongtian and Sjögren, Hans Olof and Salford, Leif and Widegren, Bengt},
  issn         = {1872-7980},
  keyword      = {DNA methylation,zebularine,IDO,immunogenicity},
  language     = {eng},
  number       = {1},
  pages        = {107--115},
  publisher    = {Elsevier},
  series       = {Cancer Letters},
  title        = {Low dose Zebularine treatment enhances immunogenicity of tumor cells},
  url          = {http://dx.doi.org/10.1016/j.canlet.2007.07.013},
  volume       = {257},
  year         = {2007},
}